![]() |
|
|
Vol. 300, Issue 2, 505-512, February 2002
Departments of Pharmacology (L.R.M., C.P.F.) and Psychiatry
(C.P.F.), The University of Texas Health Science Center at San Antonio,
San Antonio, Texas; Department of Pharmacology, Louisiana State
University Health Sciences Center, New Orleans, Louisiana (L.R.G.); and
Department of Chemistry, University of Wisconsin at Milwaukee,
Milwaukee, Wisconsin (C.M., J.M.C.)
Drug discrimination was used to examine the effects of benzodiazepine
(BZ)1 receptor-selective ligands in rhesus monkeys. In
diazepam-treated (5.6 mg/kg, p.o.) monkeys discriminating the nonselective BZ antagonist flumazenil (0.32 mg/kg, s.c.), the BZ1-selective antagonist
-carboline-3-carboxylate-t-butyl ester (
-CCt)
substituted for flumazenil. The onset of action of
-CCt was delayed
with a dose of 5.6 mg/kg
-CCt substituting for flumazenil 2 h
after injection. In monkeys discriminating the nonselective BZ agonist
midazolam (0.56 mg/kg, s.c.), the BZ1-selective agonists zaleplon (ED50 = 0.78 mg/kg) and zolpidem
(ED50 = 1.73 mg/kg) substituted for midazolam. The
discriminative stimulus effects of midazolam, zaleplon, and zolpidem
were antagonized by
-CCt (1.0-5.6 mg/kg, s.c.), and the effects of
zaleplon and zolpidem were also antagonized by flumazenil (0.01-0.32
mg/kg, s.c.). Schild analyses supported the notion of a simple,
competitive interaction between
-CCt and midazolam (slope =
1.08; apparent pA2 = 5.41) or zaleplon (slope =
1.57; apparent pA2 = 5.49) and not between
-CCt
and zolpidem. Schild analyses also were consistent with a simple,
competitive interaction between flumazenil and zaleplon (slope =
1.03; apparent pA2 = 7.45) or zolpidem (slope =
1.11; apparent pA2 = 7.63). These results suggest
that the same BZ receptor subtype(s) mediate(s) the effects of
midazolam, zolpidem, and zaleplon under these conditions and that
selective binding of BZ ligands does not necessarily confer selective
effects in vivo.
This article has been cited by other articles:
![]() |
L. P. Carter, R. R. Griffiths, P. E. Suess, J. H. Casada, C. L. Wallace, and J. D. Roache Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 749 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Sullivan, R. E. Petroski, G. Verge, R. S. Gross, A. C. Foster, and D. E. Grigoriadis Characterization of the Interaction of Indiplon, a Novel Pyrazolopyrimidine Sedative-Hypnotic, with the GABAA Receptor J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 537 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. McMahon and C. P. France Discriminative Stimulus Effects of Positive GABAA Modulators and Other Anxiolytics, Sedatives, and Anticonvulsants in Untreated and Diazepam-Treated Monkeys J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 109 - 120. [Abstract] [Full Text] [PDF] |
||||